Abstract
The direct antithrombin, bivalirudin, did not reduce angiographic restenosis measured either as the dichotomous restenosis rate of 62% for bivalirudin and 58% for heparin (p = 0.70), or as the late loss in lumen diameter of 0.44 +/- 0.47 mm for bivalirudin and 0.39 +/- 0.53 mm for heparin (p = 0.62). Direct thrombin inhibition with bivalirudin neither reduces angiographic restenosis nor alters the impact of several established risk factors for restenosis.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Angioplasty, Balloon, Coronary*
-
Antithrombins / therapeutic use*
-
Coronary Disease / diagnostic imaging
-
Coronary Disease / prevention & control*
-
Coronary Disease / therapy
-
Female
-
Heparin / therapeutic use
-
Hirudin Therapy
-
Hirudins / analogs & derivatives*
-
Humans
-
Linear Models
-
Male
-
Middle Aged
-
Peptide Fragments / therapeutic use*
-
Radiography
-
Recombinant Proteins / therapeutic use
-
Recurrence
-
Risk Factors
-
Treatment Outcome
Substances
-
Antithrombins
-
Hirudins
-
Peptide Fragments
-
Recombinant Proteins
-
Heparin
-
bivalirudin